# Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

> **NCT04364230** · PHASE1,PHASE2 · COMPLETED · sponsor: **Craig L Slingluff, Jr** · enrollment: 22 (actual)

## Conditions studied

- Melanoma
- Ocular Melanoma
- Uveal Melanoma

## Interventions

- **DRUG:** 6MHP
- **DRUG:** NeoAg-mBRAF
- **DRUG:** PolyICLC
- **DRUG:** CDX-1140

## Key facts

- **NCT ID:** NCT04364230
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364230, "Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04364230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*